Variable | All patients (n=50) |
---|---|
Clinical variables | |
Age (years) | 79±7 |
Male sex | 28 (56) |
BMI (kg/m2) | 28.4±4.6 |
NYHA class | |
I–II | 16 (32) |
III–IV | 34 (68) |
Diabetes | 15 (30) |
Hypertension | 41 (82) |
Coronary artery disease | 32 (64) |
Prior CABG | 21 (42) |
History of atrial fibrillation | 16 (32) |
Cerebrovascular disease | 7 (14) |
Peripheral vascular disease | 14 (28) |
COPD | 17 (34) |
eGFR (mL/min) | 66.2±20.8 |
LogEuroSCORE (%) | 22±13.9 |
STS-PROM (%) | 6±3.7 |
Procedural variables | |
Success* | 45 (90) |
Approach | |
Transapical | 16 (32) |
Transfemoral | 29 (58) |
Transaortic | 5 (10) |
Prosthesis type | |
Sapien | 9 (18) |
Sapien XT | 39 (78) |
Sapien 3 | 2 (4) |
Prosthesis size (mm) | |
20 | 1 (2) |
23 | 21 (42) |
26 | 17 (34) |
29 | 11 (22) |
Valve-in-valve | 9 (18) |
30-day outcomes | |
New pacemaker | 4 (8) |
Major vascular complications | 2 (4) |
Major or life-threatening bleeding | 8 (16) |
Acute renal failure | 2 (4) |
Stroke | 1 (2) |
Death | 2 (4) |
Hospitalisation length (days) | 8 (4.8, 11.5) |
Values are n (%), mean (±SD) or median [IQR].
*Following VARC-2 criteria.6
BMI, body mass index; NYHA, New York Heart Association; CABG, coronary arterial bypass graft; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration; LogEuroSCORE, logistic EuroSCORE predicted risk of mortality; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; VARC, Valve Academic Research Consortium.